

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):	David Pickar	Confirmation No.:	1878
SERIAL NUMBER:	10/522,699	EXAMINER :	Not Yet Assigned
INT'L FILING DATE:	July 28, 2003	ART UNIT :	1796
FOR:	ANTIPSYCHOTIC COMBINATION THERAPIES AND COMPOSITIONS OF AN ALPHA-2 ADRENERGIC RECEPTOR ANTAGONIST AND AN ATYPICAL ANTIPSYCHOTIC NEUROLEPTIC		

EFS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached PTO Form SB/08(a) in the above-identified application, copies of which are submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed due.

Pursuant to 37 C.F.R. §1.704(d), each item of information in this Information Disclosure Statement was first cited in a communication from a foreign patent office for counterpart Canadian Application No. 2,494,109, which was communicated to Applicants' U.S. Attorneys on April 7, 2010. As such this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this Information Disclosure Statement.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims. It is also respectfully requested that the Examiner initial, sign and date, and return a copy of the signed PTO Form SB/08(a) with the next U.S. PTO communication, to evidence that the cited information has been fully considered by the U.S. Patent and Trademark

Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. **50-0311**, Reference No. **39808-501N01US**.

Respectfully submitted,

/ Sean M. Coughlin /
Ivor R. Elrifi, Reg. No. 39,529
Sean M. Coughlin, Reg. No. 48,593
Attorneys for Applicants
MINTZ, LEVIN
Tel: (202) 585-3577
Fax: (617) 542-2241
Customer no.: 30623

Dated: May 6, 2010